All in for ALL: Mitigating VOD Risk in Patients Being Treated for R/R ALL

This series will consist of (25) virtual grand rounds programs designed to bring an expert clinician into medical centers to educate oncologists/hematologists, oncology nurses and the multidisciplinary healthcare team who are involved in the care of patients with acute lymphoblastic leukemia (ALL).

At each virtual grand rounds session, faculty will introduce the learners to a series of challenges and patient case scenarios reflecting the latest updates and unmet needs with veno-occlusive disease (VOD) risk mitigation in ALL care. Attendees will work through the key issues and then discuss their recommendations on introducing the latest multidisciplinary VOD assessment and ALL treatment strategies into practice.

All in for ALL: Mitigating VOD Risk in Patients Being Treated for R/R ALL

VPP

With the advent of new and revolutionary therapies, outcomes for patients with acute lymphoblastic leukemia have improved exponentially. Yet these therapies have a unique hepatotoxicity profile, including a higher risk of veno-occlusive disease (VOD) in recipients of hematopoietic stem cell transplant. For this reason, effective patient management must include evaluation and management of the important adverse events associated with this therapy, with a focus on diagnosis, prevention, monitoring, and management of VOD.

And while acute lymphoblastic leukemia is a rare disease and treatment is offered predominantly in academic and larger leukemia treatment centers, for many patients accessing continuous care at these large treatment centers can be difficult and community hospitals play an important role in supporting these patients closer to home.

Expiration Date: March 31, 2023

CME/CE is no longer available for this activity